As Novo Nordisk’s weight loss treatment Wegovy (semaglutide) continues its phenomenal rise, competition in the field has just stepped up with the US approval of Eli Lilly’s rival Zepbound (tirzepatide) – but other companies are banking on the market continuing to grow, with space for new entrants.
Plenty Of Room For More Obesity Drugs, Says Boehringer, As Survodutide Enters Phase III
Boehringer Ingelheim is playing catch-up with Novo Nordisk and Lilly in obesity, but is hoping a higher dose and a more patient-friendly titration can help it prove that survodutide is a contender.
More from Clinical Trials
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
• By
Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.
• By
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.